Harbinger Health Raises $100M to Develop Blood-Based Cancer Detection Tests for Symptomatic Patients
The Cambridge, Massachusetts-based firm is advancing its Resolve portfolio and Procares validation study, targeting commercial availability in the second half of 2026.
Harbinger Health said on April 14 it has raised $100 million to develop a portfolio of multi-cancer blood tests aimed at reducing the time between cancer suspicion and diagnosis in patients presenting with symptoms.
The round, raised in 2025, included Flagship Pioneering and all previous investors.
Cambridge, Massachusetts-based Harbinger Health also introduced a new product category, called Resolve, for patients with cancer symptoms who are already under clinical evaluation. The products are designed to minimize false negatives, reduce false positives, and provide information on cancer tissue of origin, the firm said in a statement.
Harbinger said the funds will support development of the initial Resolve product portfolio, advancement of its Harbinger HX detection platform, and the ongoing PROCARES prospective validation study.
“For most people who present with concerning symptoms, signs or findings, it takes months to get to a diagnosis, and mortality increases significantly with each month that goes by,” CEO Ajit Singh said in a statement. “Resolve helps clinicians move more quickly and confidently from cancer suspicion to diagnosis in people who show signs of disease, even in its earliest stages.”
Clinical study data suggest Resolve tests can shorten the time to treatment, he added. The first Resolve products are expected to be commercially available in the second half of 2026.